Frontline Use of Erythroid Maturating Agent (EMA): Luspatercept

Solly Chedid, MD, presents a patient case and provides clinical insights on approaching first-line therapy selection in patients with LR-MDS and moderate to severe anemia.

A hematologist-oncologist discusses the efficacy and safety findings from the COMMANDS trial and how they inform treatment selection.

Solly Chedid, MD, provides clinical insights on quality-of-life assessment practices for patients with MDS.

An expert on myelodysplastic syndromes reviews recent real-world data presented at EHA 2024 showing the clinical benefit of luspatercept dose titration.

Solly Chedid, MD, shares insights on optimizing anemia management in patients with lower-risk MDS and outlines remaining unmet needs in treating anemia.